Catechol-O-Methyltransferase (COMT) Gene (Val158Met) and Brain-Derived Neurotropic Factor (BDNF) (Val66Met) Genes Polymorphism in Schizophrenia: A Case-Control Study
Objective: The effects of human brain-derived neurotropic factor (BDNF) Val66Met (G>A) and the human Catechol-O-methylTransferase (COMT) Val158Met (G>A) polymorphisms on Schizophrenia (SCZ) risk were evaluated. Methods: This case control study included 92 SCZ patients and 92 healthy controls...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tehran University of Medical Sciences
2017-10-01
|
| Series: | Iranian Journal of Psychiatry |
| Subjects: | |
| Online Access: | https://ijps.tums.ac.ir/index.php/ijps/article/view/907 |
| Summary: | Objective: The effects of human brain-derived neurotropic factor (BDNF) Val66Met (G>A) and the human Catechol-O-methylTransferase (COMT) Val158Met (G>A) polymorphisms on Schizophrenia (SCZ) risk were evaluated.
Methods: This case control study included 92 SCZ patients and 92 healthy controls (HCs). Genotyping of both variants were conducted using Amplification Refractory Mutation System-Polymerase Chain Reaction (ARMS-PCR).
Results: The findings showed that BDNF Val66Met (G>A) variant increased the risk of SCZ (OR=2.008 95%CI=1.008-4.00, P=0.047, GA vs. GG, OR=3.876 95%CI=1.001-14.925, P=0.049. AA vs. GG, OR=2.272. 95%CI=1.204-4.347, P=0.011, GA+AA vs. GG, OR=2.22 95%CI=1.29-3.82. P=0.005, A vs. G). COMT Val158Met (G>A) polymorphism was not associated with the risk/protective of SCZ.
Conclusion: The results proposed that BDNF Val66Met (G>A) polymorphism may increase the risk of SCZ development and did not support an association between COMT Val158Met (G>A) variant and risk/protective of SCZ. Further studies and different ethnicities are recommended to confirm the findings. |
|---|---|
| ISSN: | 1735-4587 2008-2215 |